Canada markets closed

Emerald Health Therapeutics, Inc. (EMHTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0379+0.0039 (+11.41%)
At close: 02:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0340
Open0.0340
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0340 - 0.0400
52 Week Range0.0200 - 0.1370
Volume62,183
Avg. Volume87,637
Market Cap8.086M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.1240
Earnings DateJul 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience

    Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye") pursuant to the terms of an arrangement agreement dated May 11, 2022, as amended (the "Arrangement Agreement").On July 28, 2022, Emerald mailed to shareholders of Emerald (the "EHT Shareholders") its manageme

  • Newsfile

    Emerald Health Therapeutics, Inc. Restates Q1 Financial Statements to Meet PCAOB Standard

    Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a)

  • CNW Group

    Group of Shareholders Oppose Plan of Arrangement Between Emerald Health Therapeutics and Skye Biosciences Inc.

    Certain shareholders (the "Opposing Shareholders") of Emerald Health Therapeutics Inc. ("Emerald") (CSE: EMH); (OTCQX: EMHTF), announce that they oppose the announced plan of arrangement (the "Plan") between Emerald and Skye Biosciences Inc. ("Skye") (OTCQB: SKYE).